A.R. Abdul Razak

Inspiratory flow limitation during sleep in pre-eclampsia: comparison with normal pregnant and nonpregnant women

Geraldine Connolly, A.R. Abdul Razak, Awori J. Hayanga et al. · European Respiratory Journal · 2001 · 118 citations · Full text

Medicine, Maternal Health, Obstetrics +16

A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck

A.R. Abdul Razak, Denis Soulières, Scott A. Laurie et al. · Annals of Oncology · 2012 · 103 citations

Medicine, Oncology, Pharmacology +16

A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors

Juneko E. Grilley‐Olson, Philippe L. Bédard, Angelica Fasolo et al. · Investigational New Drugs · 2016 · 80 citations · Full text

Medicine, Oncology, Pharmacology +15

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials

Yada Kanjanapan, Daphne Day, Marcus O. Butler et al. · European Journal of Cancer · 2018 · 71 citations

Pharmacy, Immunology, Clinical Immunology +14

Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours

A.R. Abdul Razak, Sebastién J. Hotte, Lillian L. Siu et al. · British Journal of Cancer · 2011 · 66 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15